埃罗替尼靶向治疗对非小细胞肺癌患者免疫功能及生存时间的影响  

Effect of Erlotinib Targeted Therapy on Immune Function and Survival Time of Patients with Non-small Cell Lung Cancer

作　　者：李昆松 Li Kunsong(Guangzhou Medical University,Guangzhou 511483 Guangdong)

机构地区：[1]广州医科大学,广东广州511483

出　　处：《黄冈职业技术学院学报》2020年第3期104-106,共3页Journal of Huanggang Polytechnic

摘　　要：目的评价埃罗替尼靶向治疗对非小细胞肺癌患者免疫功能及生存时间的影响。方法分析非小细胞肺癌患者为研究观察主体,抽选出92例以双色球摸球法均匀分成两组,对照组接受GP化疗,观察组联合埃罗替尼靶向治疗,对比两组患者的免疫功能、生存时间及临床效果。结果观察组治疗效果显著优于对照组,其生存率明显比对照组高,治疗后观察组患者的免疫功能改善效果明显优于对照组,组间对比差异显著。结论临床治疗非小细胞肺癌采取化疗+埃罗替尼靶向治疗可延长患者的生命周期,改善其免疫功能。Objective To evaluate the effect of erlotinib targeted therapy on immune function and survival time of patients with non-small cell lung cancer(NSCLC).Methods 92 patients with non-small cell lung cancer were selected and divided into two groups by double color ball touching method.The control group received GP chemotherapy,and the observation group combined with erlotinib targeted therapy.The immune function,survival time and clinical effect of the two groups were compared.Results The treatment effect of the observation group was significantly better than that of the control group,and its survival rate was significantly higher than that of the control group.After treatment,the immune function of the observation group was significantly better than that of the control group,and the difference between the two groups was significant.Conclusion Chemotherapy combined with erlotinib targeted therapy can prolong the life cycle of patients with NSCLC and improve their immune function.

关 键 词：埃罗替尼 靶向治疗 非小细胞肺癌 免疫功能 生存时间 

分 类 号：R421[医药卫生—临床医学]